Antengene receives Thailand FDA approval to commercialize Xpovio in Thailand
Antengene's Xpovio (selinexor) receives Thailand FDA approval for multiple myeloma treatments, expanding its reach in APAC. Xpovio, an orally-available selective XPO1 inhibitor, aims to improve clinical management of MM in Thailand and other ASEAN markets. Antengene plans further expansion and development of Xpovio combinations for various cancers.
© Copyright 2024. All Rights Reserved by MedPath